Abcam, ab255780, Anti-DLL1 antibody [1F9] - BSA and Azide free

Size: 100µg / 1mg
Rat Recombinant Monoclonal DLL1 antibody. Carrier free. Suitable for WB and reacts with Mouse samples.
Key facts
Host species:Rat,
Clonality:Monoclonal,
Clone number:1F9,
Isotype:IgG2a,
Carrier free:Yes,
Reacts with:Mouse,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab255780 is the carrier-free version of
ab252824
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Ion exchange chromatography, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein known as Delta-like 1 (DLL1) also referred to as DLL 1 or DLL1 protein is an essential component in various cellular mechanisms. DLL1 typically has a molecular mass of approximately 80 kDa. This protein is mainly expressed in tissues related to development such as the nervous system bone marrow and certain parts of the embryonic organs. DLL1 functions mechanic-wise as a ligand for the Notch receptor family playing a role in signal transduction and influencing cell fate decisions.
Biological function summary
Delta-like 1 protein is involved in several cell differentiation processes impacting tissue development. The protein is a member of the Notch signaling pathway which is important for mediating communication between adjacent cells. It interacts with Notch receptors to regulate transcriptional activities and promote different cell lineages. DLL1 does not function in isolation; it works as a part of a larger protein complex that includes intracellular domains and other signal modifiers.
Pathways
Delta-like 1 fits into the Notch signaling pathway and the Wnt pathway. In the Notch signaling pathway DLL1 engages with Notch receptors to drive transcriptional responses important for embryogenesis and cell fate choices. In the Wnt pathway DLL1 interacts to modulate cellular growth and differentiation often in conjunction with proteins such as Jagged1 and Notch1. These pathways are essential in maintaining stem cell niches and influencing neurogenesis.
Delta-like 1 protein bears significance in oncological and congenital disorders. Dysregulation of DLL1 is associated with cancers like T-cell acute lymphoblastic leukemia where altered Notch signaling plays a role in tumor progression. Additionally abnormalities in DLL1 expression relate to congenital heart defects indicating its role in cardiac development. DLL1's interaction with Notch receptors such as Notch3 appears significant in these contexts making it a potential target for therapeutic intervention in both cancer and congenital disorder management.